Differential oxidative response to fluoropyrimidines in colorectal cancer cell lines

Colorectal cancer (CRC) is the second most common human malignancy in women and the third in men, accounting for approximately 8% of cancer-related deaths and 1.3 million newly diagnosed cases annually worldwide. CRC cell lines differ in morphological features, growth rate, and their genetic alterations, implicating the extent of variability among the lines. The goal of the current study was to investigate the phenotypes of CRC lines related to NADPH oxidase (NOX) activity and expression of NOX2 subunits in response to fluoropyrimidines. NOX activity in response to 5 -fluoro-2 -deoxyuridine (FdUrd) and VAS2780 was measured in CRC cell lines. Cells were treated with FdUrd in order to determine apoptotic cell death and mRNA expressions of NOX2 cytoplasmic subunits. We find that both basal and drug-induced NOX activity differ in the lines. Similarly, drug-mediated apoptotic indices vary in the cell lines at basal levels. Among NOX1 and NOX2 subunits, only NOX2 accessory subunits, p67phox, p40phox, and p47phox, differ in the lines. Our results show that CRC cells have diverse oxidative background and their oxidative response to anticancer drugs vary, while they all exhibit increases in NOX activity.

PDF

___

Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknæs M, Hektoen M, Lind GE, Lothe RA (2013). Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2: e71.
Alexandre J, Batteux F, Nicco C, Chéreau C, Laurent A, Guillevin L, Weill B, Goldwasser F (2006). Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 119: 41-48.
Altenhöfer S, Kleikers PW, Radermacher KA, Scheurer P, Rob Hermans JJ, Schiffers P, Ho H, Wingler K, Schmidt HH (2012). The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cell Mol Life Sci 69: 2327-2343.
Bedard K, Krause KH (2007). The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313.
Berger FG, Berger SH (2006). Thymidylate synthase as a chemotherapeutic drug target: where are we after fifty years? Cancer Biol Ther 5: 1238-1241.
Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le Floch O (2009). Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer 101: 1978-1985.
Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE (1981). Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 41: 1751-1756.
Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N (2010). Colorectal cancer. Lancet 375: 1030-1047.
Danenberg PV (1977). Thymidylate synthetase a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473: 73-92.
de Anta JM, Mayo C, Solé F, Salido M, Espinet B, Corzo C, Petzold M, Villa O, Serrano S, Real FX et al (2006). Methotrexate resistance in vitro is achieved by a dynamic selectionprocess of tumor cell variants emerging during treatment. Int J Cancer 119: 1607-1615.
Fidler IJ, Poste G (1985). The cellular heterogeneity of malignant neoplasms. Implications for adjuvant chemotherapy. Semin Oncol 12: 207-221.
Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad Ø (2004). Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice. Eur J Cancer 40: 1593-1598.
Gallego MA, Ballot C, Kluza J, Hajji N, Martoriati A, Castera L, Cuevas C, Formstecher P, Joseph B, Kroemer G et al (2008). Overcoming chemoresistance of non-small cell lung carcinoma through restoration of an AIF-dependent apoptotic pathway. Oncogene 27: 1981-1992.
Hwang IT, Chung YM, Kim JJ, Chung JS, Kim BS, Kim HJ, Kim JS, Yoo YD (2007). Drug resistance to 5-FU linked to reactive oxygen species modulator 1. Biochem Biophys Res Commun 359: 304-310.
Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RAJ, Kinzler KW, Vogelstein B (2001). Ferredoxin reductase affects p53-dependent, 5-fluorouracilinduced apoptosis in colorectal cancer cells. Nature Medicine 7: 1111- 1117.
Juhasz A, Ge Y, Markel S, Chiu A, Matsumoto L, van Balgooy J, Roy K, Doroshow JH (2009). Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues. Free Radic Res 43: 523- 532.
Krokan HE, Drablos F, Slupphaug G (2002). Uracil in DNA occurrence, consequences and repair. Oncogene 21: 8935- 8948.
Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK (2008). Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 68: 1777-1785.
Lambeth JD (2004). NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 4: 181-189.
Laurent A, Nicco C, Chereau C, Goulvestre C, Alexandre J, Alves A, Levy E, Goldwasser F, Panis Y, Soubrane O et al (2005). Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 65: 948-956.
Leibovitz A, Stinson JC 3rd, McCombs WB, McCoy CE, Mazur KC, Mabry ND (1976). Classification of human colorectal adenocarcinoma cell lines. Cancer Res 36: 4562-4569.
Longley DB, Harkin DP, Johnston PG (2003). 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338.
Lucas AS, ONeil BH, Goldberg RM (2011). A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 10: 238-244.
McBain JA, Weese JL, Meisner LF, Wolberg WH, Willson JK (1984). Establishment and characterization of human colorectal cancer cell lines. Cancer Res 44: 5813-5821.
Milano G, Ferrero JM, Francois E (2004). Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Br J Cancer 91: 613-617.
ODwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC et al (1996). Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 14: 249-256.
Ozer U, Barbour KW, Clinton SA, Berger FG (2015). Oxidative stress and response to thymidylate synthase-targeted therapy. Mol Pharmacol 88: 970-981.
Platell C, Ng S, OBichere A, Tebbutt N (2011). Changing management and survival in patients with stage IV colorectal cancer. Dis Colon Rectum 54: 214-219.
Ribas M, Masramon L, Aiza G, Capellà G, Miró R, Peinado MA (2003). The structural nature of chromosomal instability in colon cancer cells. FASEB J 17: 289-291.
Schmid J, Dussmann H, Boukes GJ, Flanagan L, Lindner AU, OConnor CL, Rehm M, Prehn JH, Huber HJ (2012). Systems analysis of cancer cell heterogeneity in caspase-dependent apoptosis subsequent to mitochondrial outer membrane permeabilization. J Biol Chem 287: 41546-41559.
Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, Hirohashi S (2008). Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135: 1358-1368.
Siegel RL, Miller KD, Jernal A (2015). Cancer statistics. CA Cancer J Clin 65: 5-29.
Soong R, Diasio RB (2005). Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics 6: 835-847.
Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D et al (2008). Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 19: 915-919.
Sotos GA, Grogan L, Allegra CJ (1994). Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 20: 11-49.
Spears CP, Gustavsson BG, Berne M, Frosing R, Bernstein L, Hayes AA (1988). Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 48: 5894-5900.
Stein A, Atanackovic D, Bokemeyer C (2011). Current standards and new trends in the primary treatment of colorectal cancer. Eur J Cancer 47 Suppl 3: S312-S314.
Ueta E, Yoneda K, Yamamoto T, Osaki T (1999). Manganese superoxide dismutase negatively regulates the induction of apoptosis by 5-fluorouracil, peplomycin and γ-rays in squamous cell carcinoma cells. Jpn J Cancer Res 90: 555-564.
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL (1988). Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532.
Wyatt MD, Wilson DM (2009). Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 66: 788-799.